HEV infection in two referral centers in Spain: epidemiology and clinical outcomes

J Clin Virol. 2015 Feb:63:76-80. doi: 10.1016/j.jcv.2014.12.017. Epub 2014 Dec 26.

Abstract

Background and objectives: Hepatitis E virus (HEV) is one of the major causes of icteric hepatitis worldwide. In industrialized countries it is considered an emerging disease, as a growing number of autochthonous cases have been reported in recent years. Occasional extrahepatic manifestations have been described in the setting of HEV infection.

Study design: To characterize the epidemiological pattern and clinical outcomes of new cases of HEV infection diagnosed in two referral centers during the period 2011-2013.

Results: During the study period, four cases of self-limited acute hepatitis E after travel to endemic areas were recorded, as well as five cases of HEV infection after solid organ transplantation. Four patients failed to spontaneously clear the virus and received ribavirin monotherapy; all of them had HEV genotype-3. Ribavirin was effective in inhibiting HEV replication, although in one patient a virological relapse occurred after the end of therapy. Finally, we report a case of HEV-genotype-3 related agranulocytosis in an immunocompetent patient, resulting in a fatal outcome; this is the first case reported of its kind.

Conclusion: Diagnosis of HEV infection needs to be taken into consideration in patients with acute or chronic hepatitis in whom other etiologies have been excluded. Although hematological complications related to acute HEV infection are infrequent, these may affect any of the bone marrow series, even after viral clearance.

Keywords: Agranulocytosis; Hepatitis E; Ribavirin; Transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • Female
  • Hepatitis E / drug therapy
  • Hepatitis E / epidemiology*
  • Hepatitis E / pathology*
  • Humans
  • Male
  • Middle Aged
  • Organ Transplantation*
  • Ribavirin / therapeutic use
  • Spain / epidemiology
  • Travel*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Ribavirin